For the latest COVID-19 campus news and resources, visit umassmed.edu/coronavirus.

Buscar Close Search
Buscar Close Search
Profile Picture for Xue

Wen Xue, PhD

Associate Professor, RNA Therapeutics Institute

Research Focus - CRISPR-Cas Genome Development of Cancer Models

  • Mouse models of cancer
  • Use CRISPR genome editing to functionally dissect cancer mutations in liver and lung cancer

Representative Publications

  • AAV5 delivery of CRISPR-Cas9 supports effective genome editing in mouse lung airway. Liang SQ, Walkey CJ, Martinez AE, Su Q, Dickinson ME, Wang D, Lagor WR, Heaney JD, Gao G, Xue W.Mol Ther. 2021 Oct 23:S1525-0016(21)00530-X. doi: 10.1016/j.ymthe.2021.10.023. Online ahead of print.PMID: 34695545 Read Publication

In the News

  • Wen Xue receives $250,000 for pediatric cancer research from Hyundai Hope on Wheels
    Research News

    Wen Xue receives $250,000 for pediatric cancer research from Hyundai Hope on Wheels

    UMass Medical School cancer researcher Wen Xue, PhD, accepted a $250,000 grant Friday from the Hyundai Motor America Hope on Wheels campaign to continue his work toward improving care and treatment options for children with cancer.

    Read more
  • CRISPR/Cas9 therapeutic for Tyrosinemia type I delivered to mice
    Research News

    CRISPR/Cas9 therapeutic for Tyrosinemia type I delivered to mice

    According to a study published in Nature Biotechnology, a more efficient delivery of a CRISPR/Cas9 therapeutic to adult mice with the metabolic disease Tyrosinemia type I developed by Wen Xue, PhD, may also prove to be safer for use in humans.

    Read more
  • MD/PhD-student-led research finds potential new gene target for pediatric liver cancer
    Research News

    MD/PhD-student-led research finds potential new gene target for pediatric liver cancer

    A new study by a team of UMass Medical School researchers, led by Jordan Smith, MD/PhD candidate, has identified a new therapeutic target in hepatoblastoma, a rare, primarily pediatric liver cancer.

    Read more
  • Flotte lab to develop gene therapy models for genetic lung disease
    Research News

    Flotte lab to develop gene therapy models for genetic lung disease

    Researchers from UMass Chan Medical School have received a five-year $13.6 million program project grant from the National Heart, Lung and Blood Institute to develop new gene therapy models for alpha-1 antitrypsin deficiency, a chronic, debilitating genetic lung disease that shortens the lifespan.

    Read more
  • Erik Sontheimer co-leading efforts to develop gene editing toolkit by NIH Somatic Cell Genome Editing Consortium
    Research News

    Erik Sontheimer co-leading efforts to develop gene editing toolkit by NIH Somatic Cell Genome Editing Consortium

    Six UMass Medical School scientists are among the members of the National Institutes of Health’s Somatic Cell Genome Editing Consortium to publish a paper in Nature outlining the program’s goals.

    Read more